ERBB2 and cancer: In this study, we report the pan-tumor landscape of ERBB2 and ERBB3 activating alterations across a combined cohort of >500,000 patients with either Foundation Medicine or Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) comprehensive genomic profiling (CGP).